Should metformin remain the first-line therapy for treatment of type 2 diabetes?

Although some show differences in the hazard ratios between metformin users versus non-users, the analysis for heterogeneity or treatment by subgroup interaction did not reach statistical significance, suggesting that the presence of metformin for the cardio-protective effects is not required.

also in 111,027 other papers